BioTuesdays

Tag - Cantor Fitzgerald

Annexon-biosciences

Cantor starts Annexon at OW; PT $40

Cantor Fitzgerald initiated coverage of Annexon (NASDAQ:ANNX) with an “overweight” rating and $40 price target. The stock closed at $21.12 on Sept. 22. Annexon is a platform-enabled therapeutics company focused on...

Clarus-Therapeutics

Cantor starts Clarus Therapeutics at OW; PT $20

Cantor Fitzgerald initiated coverage of Clarus Therapeutics (NASDAQ:CRXT) with an “overweight” rating and $20 price target. The stock closed at $8.81 on Sept. 17. Clarus is focused on developing androgen and metabolic...

Equillium

Cantor starts Equillium at OW, PT $14

Cantor Fitzgerald launched coverage of Equillium (NASADQ:EQ) with an “overweight” rating and $14 price target. The stock closed at $5.40 on Sept. 14. Equillium is developing itolizumab, its novel CD6 targeted monoclonal...

Effector-Therapeutics

Cantor starts eFFECTOR Therapeutics at OW; PT $50

Cantor Fitzgerald launched coverage of eFFECTOR Therapeutics (NASDAQ:EFTR) with an “overweight” rating and price target of $50. The stock closed at $26.59 on Sept. 10. eFFECTOR is focused on developing a new class of...

Portage

Cantor starts Portage Biotech at OW; PT $35

Cantor Fitzgerald launched coverage of Portage Biotech (NASDAQ:PRTG) with an “overweight” rating and $35 price target. The stock closed at $18.95 on Aug. 18.  Portage Biotech is a clinical biopharmaceutical company...

Nyxoah

Cantor starts Nyxoah at OW; PT $43

Cantor Fitzgerald initiated coverage of Nyxoah SA (NASDAQ:NYXH) with an “overweight” rating and 12-month price target of $43, citing the company’s “pipeline and uniquely differentiated product”. The stock closed at $32...

SELLAS Life Sciences Logo

Cantor starts SELLAS Life Sciences at OW; PT $18

Cantor Fitzgerald launched coverage of SELLAS Life Sciences (NASDAQ:SLS) with an “outperform” rating and $18 price target. The stock closed at $8.60 on July 20. SELLAS is a late-stage immune-oncology company that is...

Novan logo

Cantor starts Novan at OW; PT $30

Cantor Fitzgerald initiated coverage of Novan (NASDAQ:NOVN) with an “overweight” rating and $30 price target. The stock closed at $9.10 on July 8. Novan is a clinical-stage biotechnology company focused on leveraging...